Abstract
When developing new medication for rheumatoid arthritis (RA), complementary animal models are used to predict clinical effects. These models cause substantial discomfort to the experimental animals. It is unknown how effective the animal models are in predicting clinical efficacy.
The clinical trials and animal studies for the classical disease-modifying anti-rheumatic drugs (DMARDs) are accepted as a viable research tool. Methotrexate is a widely used DMARD. Presently a clear overview of the used experimental designs and the differences between designs in clinical trials and animal studies is lacking. It will be provided by this SR.
The clinical trials and animal studies for the classical disease-modifying anti-rheumatic drugs (DMARDs) are accepted as a viable research tool. Methotrexate is a widely used DMARD. Presently a clear overview of the used experimental designs and the differences between designs in clinical trials and animal studies is lacking. It will be provided by this SR.
Original language | English |
---|---|
Type | Protocol |
Media of output | Website |
Number of pages | 7 |
Place of Publication | www.syrcle.nl |
Publication status | Published - 19 Feb 2016 |